European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases
EU RESPONSE
The project aims to identify potential treatments for the disease COVID-19, verify the safety and effectiveness of such treatments, and prepare Europe for possible future pandemics. The EU-Response project includes 2 international multicenter randomized clinical trials, namely Discovery and EU-SolidAct. The Discovery clinical trial is currently focused on verifying the safety and efficacy of monoclonal antibodies. EU-SolidAct is a platform-based trial with an adaptive design that enables the testing of different therapeutic options for the disease COVID-19 in a short time according to the latest scientific findings, while building a clinical research network in Europe, thereby improving Europe’s ability and preparedness to respond to pandemic crises. Through this project, UPJŠ brings innovative therapy for the disease COVID-19 to Slovak patients and enables them to benefit from the latest scientific knowledge and integrates Slovakia into the European area of clinical research.
In 2023, the Discovery and EU-SolidAct clinical trials were terminated and the active clinical trial centers were closed. The building of a network connecting clinical research centers in Europe continues.
Programme: H2020
Call: H2020-IBA-SC1-CORONAVIRUS-2020-3H2020-IBA-SC1-CORONAVIRUS-2020-3
Project duration: 1. 7. 2020 – 30. 6. 2025
Responsible persons:
prof. MVDr. Monika Halánová PhD.
MVDr. Simona Sonderlichová
Consortium:
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE – INSERM (coordinator)
- ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK – ECRIN
- FOLKEHELSEINSTITUTTET – NORWEGIAN INSTITUTE OF PUBLIC HEALTH NIPH
- OSLO UNIVERSITETSSYKEHUS HF – OUS
- UNIVERSITA DEGLI STUDI DI VERONA – UNIVR
- UNIDADE LOCAL DE SAUDE DE SAO JOAO, E.P.E. – ULSSJ
- NSERM TRANSFERT SA
- UNIVERZITA PAVLA JOZEFA SAFARIKA V KOSICIACH – UPJS
- UNIVERSITE LIBRE DE BRUXELLES – ULB
- SZEGEDI TUDOMANYEGYETEM – USZ
- UNIVERSITY COLLEGE CORK – NATIONAL UNIVERSITY OF IRELAND, CORK – UCC
- SWISS CLINICAL TRIAL ORGANISATION (SCTO) – SCTO
- HACETTEPE UNIVERSITESI
- CENTRE HOSPITALIER DE LUXEMBOURG – CHL
- ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE GEMEINNUTZIGE GMBH – AGMT
- SSISTANCE PUBLIQUE HOPITAUX DE PARIS
- HOSPICES CIVILS DE LYON
- SERVICIO MADRILENO DE SALUD – SERMAS
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON – UOA
- UNIVERSYTET MEDYCZNY W LODZI. – LODZ
- UNIVERZITA KARLOVA – CU
- GESUNDHEIT NORD GGMBH KLINIKVERBUNDBREMEN
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 101015736.
